Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11598728 | 0.98 | MAPT (0.36) | MAPTHSD17B10 | |
| SCHEMBL2846172 | 0.77 | MAPT (0.33) | MAPT | |
| SCHEMBL28703370 | 0.75 | HSD17B10 (0.37) | MAPTHSD17B10 | |
| SCHEMBL7790929 | 0.75 | — | — | |
| SCHEMBL7788012 | 0.75 | — | — | |
| SCHEMBL4422411 | 0.75 | GAA (0.30) | — | |
| SCHEMBL11007064 | 0.75 | L3MBTL1 (0.35) | — | |
| SCHEMBL2241240 | 0.74 | HSD17B10 (0.32) | HSD17B10 | |
| SCHEMBL11658038 | 0.74 | MAPT (0.31) | MAPT | |
| SCHEMBL441379 | 0.72 | CA1 (0.31) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1362023-B1 | METHOD FOR PRODUCING MACROCYCLIC KETONES | GIVAUDAN SA (CH) | 2009-04-15 | — | — | EP | disclosed |
| US-6951964-B2 | Method for producing macrocyclic ketones | GIVAUDAN SA (CH) | 2005-10-04 | — | — | US | disclosed |
| US-20040082816-A1 | Method for producting macrocyclic ketones | GIVAUDAN SA (CH) | 2004-04-29 | — | — | US | disclosed |
| EP-1362023-A1 | METHOD FOR PRODUCING MACROCYCLIC KETONES | Givaudan SA (CH) | 2003-11-19 | — | — | EP | disclosed |
| WO-2002068372-A1 | METHOD FOR PRODUCING MACROCYCLIC KETONES | GIVAUDAN SA (CH) | 2002-09-06 | — | — | WO | disclosed |
| EP-1236707-A1 | Process for the preparation of macrocyclic ketones | Givaudan SA (CH) | 2002-09-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040082816-A1 | Method for producting macrocyclic ketones | ADH1C, ADH1A, AKR1C3 | MAPT 3322/4885HSD17B10 40/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.